Chemotherapy in India and UAE | Complete Patient Guide

• Newly diagnosed solid tumor patients (breast, lung, colorectal, gastric, ovarian, bladder, cervical, head & neck) requiring first-line, adjuvant, or neoadjuvant systemic therapy

• Hematologic malignancy patients (lymphoma, leukemia, multiple myeloma) requiring induction, consolidation, or salvage chemotherapy

• Patients with metastatic or locally advanced disease where chemotherapy is combined with immunotherapy (checkpoint inhibitors: pembrolizumab, nivolumab, atezolizumab) or targeted agents

• Candidates for high-dose chemotherapy (HDC) with autologous stem cell rescue (ASCT) for relapsed/refractory lymphoma or multiple myeloma

• Patients requiring intrathecal chemotherapy for CNS involvement or prophylaxis (e.g., methotrexate, cytarabine in ALL)

• Patients with resectable tumors where neoadjuvant chemotherapy is intended to downstage disease prior to surgery (e.g., FLOT protocol for gastric cancer, NACT for locally advanced breast cancer)

Required Pre-Treatment Diagnostics:

• PET-CT scan (18F-FDG) for staging and treatment response assessment (Deauville criteria for lymphoma; RECIST 1.1 for solid tumors)

• Biopsy with comprehensive immunohistochemistry (IHC), in-situ hybridization (FISH/ISH), and next-generation sequencing (NGS) panel for molecular profiling

• Complete blood count with differential, comprehensive metabolic panel (renal and hepatic function), serum LDH, beta-2 microglobulin, tumor markers (CEA, CA125, AFP, beta-hCG, PSA as applicable)

• Echocardiogram (ECHO) or MUGA scan (mandatory before anthracyclines; baseline LVEF must be ≥50%)

• Pulmonary function tests (PFTs) before bleomycin-containing regimens

• Audiometry before cisplatin-based therapy

• DPYD, TPMT, UGT1A1 pharmacogenomic testing where applicable (5-FU, thiopurines, irinotecan)

• Bone marrow biopsy for hematologic staging (lymphoma, leukemia, myeloma)

• Brain MRI for CNS staging in high-risk histologies (DLBCL, SCLC, melanoma)

• Fertility counseling and oocyte/sperm cryopreservation referral for premenopausal women and young men

• COVID-19/infection screening and dental evaluation before high-dose or immunosuppressive regimens

Contraindications and Relative Contraindications:

• ECOG Performance Status ≥3–4 (poor functional status; consider palliative-intent dose reduction)

• Severe renal impairment (eGFR <30 mL/min): cisplatin is contraindicated; carboplatin requires AUC-based dose adjustment (Calvert formula)

• Hepatic impairment (Child-Pugh B/C): impaired metabolism of doxorubicin, vincristine, and paclitaxel necessitates dose modification or alternative agents

• Severely depressed baseline bone marrow function (ANC <1,000/µL, platelets <75,000/µL) without correctable cause

• Active severe infection or sepsis (defer until controlled)

• LVEF <50% (relative contraindication for anthracyclines; reassess with cardio-oncology consultation)

• Pregnancy (most cytotoxic agents are teratogenic in first trimester; select agents can be used in second/third trimester with multidisciplinary oversight)

• Known severe hypersensitivity reactions to specific chemotherapy agents without viable alternatives

Chemotherapy is not a single treatment but a spectrum of regimens, delivery routes, and combination strategies, individualized based on tumor histology, molecular subtype, stage, comorbidities, and performance status.

Standard Systemic Intravenous Chemotherapy: The foundation of most regimens. Multi-agent combinations are preferred over single agents to overcome drug resistance. Key backbone regimens include: AC-T (doxorubicin + cyclophosphamide followed by paclitaxel) for breast cancer; FOLFOX (5-fluorouracil + leucovorin + oxaliplatin) or FOLFIRI + bevacizumab/cetuximab for colorectal cancer; BEP (bleomycin + etoposide + cisplatin) for germ-cell tumors; R-CHOP (rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone) for DLBCL; ABVD (doxorubicin + bleomycin + vinblastine + dacarbazine) for Hodgkin lymphoma; and platinum doublets (carboplatin/paclitaxel ± pembrolizumab) for NSCLC. Cycles are typically administered every 2–3 weeks through a peripherally inserted central catheter (PICC line) or implantable port (Port-a-Cath), reducing venous access complications across 4–8 cycles.

Dose-Dense and Dose-Intensified Regimens: Dose-dense AC-T (every 2 weeks with G-CSF support) has demonstrated superior disease-free survival in high-risk breast cancer compared to standard 3-weekly scheduling. Escalated BEACOPP is used for advanced-stage Hodgkin lymphoma in fit patients (age <60, ECOG 0–1) where superior tumor control outweighs increased toxicity. Dose intensity is managed with prophylactic G-CSF (filgrastim, pegfilgrastim) to prevent febrile neutropenia.

High-Dose Chemotherapy with Autologous Stem Cell Transplantation (HDC-ASCT): Used in relapsed/refractory Hodgkin lymphoma (BEAM conditioning: carmustine + etoposide + cytarabine + melphalan), multiple myeloma (melphalan 200 mg/m² conditioning), and selected DLBCL. Stem cells are harvested after mobilization with G-CSF ± plerixafor, cryopreserved, and reinfused 24–72 hours after myeloablative conditioning. Leading Indian centres (Tata Memorial Hospital, Apollo, Fortis) and UAE centres (Cleveland Clinic Abu Dhabi, Burjeel) perform ASCT within dedicated BMT units with HEPA-filtered positive-pressure rooms.

Targeted Therapy Combined with Chemotherapy: Molecular profiling drives combination strategies. HER2-positive breast cancer: trastuzumab + pertuzumab + docetaxel (TCHP). EGFR-mutant NSCLC: osimertinib (third-generation EGFR TKI) is now often preferred as monotherapy, but platinum-based doublets remain standard for EGFR-wild-type disease. Ovarian cancer: carboplatin + paclitaxel + bevacizumab, with PARP inhibitor maintenance (olaparib, niraparib) in BRCA-mutated patients. CML and Ph+ ALL: BCR-ABL TKIs (imatinib, dasatinib, ponatinib) combined with cytotoxic induction chemotherapy.

Immunotherapy-Chemotherapy Combinations (Chemo-Immunotherapy): Checkpoint inhibitor combinations represent the most significant evolution in first-line oncology over the past decade. Pembrolizumab + carboplatin/paclitaxel for NSCLC (KEYNOTE-189/590). Atezolizumab + nab-paclitaxel for triple-negative breast cancer (PD-L1+). Nivolumab + FOLFOX for HER2-negative gastric/GEJ adenocarcinoma. These regimens require PD-L1 IHC scoring and, in some cases, MSI/TMB analysis to guide patient selection.

Regional and Specialized Delivery Routes: Intraperitoneal (IP) chemotherapy (cisplatin + paclitaxel IP) is used in optimally debulked ovarian cancer following cytoreductive surgery. Hyperthermic Intraperitoneal Chemotherapy (HIPEC) delivers heated cytotoxic agents (typically mitomycin-C or oxaliplatin at 41–43°C) directly into the peritoneal cavity during surgery for peritoneal surface malignancies (colorectal, appendiceal, gastric, ovarian). Intrathecal chemotherapy (methotrexate, cytarabine, hydrocortisone via lumbar puncture) treats or prevents CNS involvement in ALL, aggressive lymphomas, and leptomeningeal metastases. Hepatic arterial infusion (HAI) with floxuridine (FUDR) is used for colorectal liver metastases at specialized centres. Intravesical chemotherapy (mitomycin-C) is a standard adjunct after TURBT for non-muscle-invasive bladder cancer.

Antibody-Drug Conjugates (ADCs): ADCs represent a precision evolution of chemotherapy: a cytotoxic payload is conjugated to a tumor-targeting antibody. Trastuzumab deruxtecan (T-DXd/Enhertu) for HER2-positive/low breast cancer and NSCLC; sacituzumab govitecan (Trodelvy) for triple-negative breast cancer and urothelial carcinoma; brentuximab vedotin (Adcetris) for CD30+ lymphomas; polatuzumab vedotin (Polivy) for DLBCL. These agents are now available at leading oncology centres in both India and the UAE.

Pre-Treatment Phase (Weeks 1–3 before Cycle 1): Step 1 — Remote Case Submission: Patient submits pathology reports, imaging (PET-CT, MRI, CT), operative notes, and prior treatment records to GAF Healthcare's oncology coordination team. A medical oncologist in India or the UAE performs a virtual consultation within 48–72 hours. Step 2 — Multidisciplinary Tumor Board Review: The treating centre convenes a tumor board (medical oncologist, radiation oncologist, surgical oncologist, pathologist, radiologist) to confirm diagnosis, review molecular profiling (NGS/IHC), and ratify the treatment regimen per NCCN/ESMO guidelines. Step 3 — Travel and Arrival: GAF Healthcare arranges the e-Medical visa (India) or UAE entry visa. The patient and one attendant arrive; airport transfer to accredited hospital or partner accommodation is coordinated. Step 4 — Baseline Work-Up (Day 1–3): Repeat or confirmatory imaging, blood panel, ECHO/PFTs/audiometry as required, pharmacogenomic testing, central venous access placement (PICC line or Port-a-Cath implant under local anesthesia), and a pre-chemotherapy anesthesia/cardiac risk assessment. Step 5 — Patient Education and Supportive Care Planning: Dietitian consultation (nutritional optimization, antiemetic dietary guidance), oncology nurse education on self-monitoring for fever/neutropenia, dental clearance, and fertility preservation referral if applicable.

Chemotherapy Administration (Per Cycle): Step 6 — Cycle 1 (Day 1 of Treatment): Pre-medications administered IV (antiemetics: ondansetron, dexamethasone, aprepitant for highly emetogenic regimens; antihistamines and steroids for taxane hypersensitivity prophylaxis). Chemotherapy infusion administered in a dedicated oncology day-care unit under continuous nursing monitoring. Duration ranges from 1 hour (single-agent IV push) to 48–96 hours (continuous 5-FU infusion via ambulatory pump). Vital signs, allergic reactions, and infusion-related reactions are monitored in real time. Step 7 — Nadir Period (Days 7–14): The period of maximum myelosuppression. CBC is monitored at nadir (typically Day 10–14). G-CSF support (pegfilgrastim Day 2 of each cycle) is administered for dose-dense or high-risk regimens. Patients are educated on fever protocols (any temperature ≥38.3°C requires immediate hospital presentation for febrile neutropenia assessment and empiric broad-spectrum antibiotics). Step 8 — Cycle Recovery and Re-Assessment (Day 15–21): Blood counts recover; fitness for next cycle confirmed by ANC ≥1,500/µL and platelets ≥100,000/µL. Interim imaging (CT or PET-CT) performed after cycles 2–4 to assess treatment response (RECIST 1.1 / Deauville criteria).

Multi-Cycle Regimen (Months 1–6): Step 9 — Cycles 2–8: Repeat administration per schedule (every 2 or 3 weeks). Between cycles, patients may be permitted to return home or stay in local accommodation coordinated by GAF Healthcare. GAF provides telemedicine access to the treating oncologist for symptom management and lab result review during intervals.

End-of-Treatment Evaluation: Step 10 — Post-Treatment Restaging Scan (Week 2–4 after final cycle): PET-CT or CT chest/abdomen/pelvis for response assessment. Complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD) determines subsequent management (surveillance, consolidation radiation, maintenance therapy, or salvage). Step 11 — Fit-to-Fly Clearance: The treating oncologist confirms bone marrow recovery (ANC ≥1,000/µL, no active infection, adequate renal/hepatic function). A discharge summary, treatment record, and next follow-up plan in the home country are provided. GAF Healthcare coordinates the return airport transfer and assists with medical record forwarding to the patient's home oncologist. Step 12 — Ongoing Remote Follow-Up: GAF Healthcare facilitates telemedicine follow-up consultations with the treating oncologist at 4–6 week intervals, coordinating local lab result upload and imaging review for patients who have returned home.